As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Family involvement in psychedelic therapy can optimize outcomes and prevent problematic patterns. Ethical, neurobiological, and psychological aspects, along with clinical trial data, support the benefits of engaging family members.
Jennifer Danby
Psilocybin's therapeutic potential for various medical conditions is being explored, including pilot studies on Alzheimer's Disease and chronic Lyme Disease. Preliminary results and participant reports inform ongoing psilocybin-assisted treatments research.
Albert Garcia-Romeu
Psychedelics, historically linked to "free love", show potential for positive impact on sexual feelings. Recent research suggests psilocybin may enhance sexual functioning and satisfaction in healthy and depressed individuals.
Tommaso Barba
Hardman provides a quick overview of the emerging psychedelic sector, covering financial, research, and policy landscapes with data visuals. He also explores unanswered questions about the sector's future.
Josh Hardman
Elliot Cohen (Pillpack, Amazon) and Protik Basu (World Bank, UN, Helena) share insights on healthcare delivery, psychedelics industry, scaling challenges, and technology's role in patient care.
Andrew “Mo” Septimus, Protik Basu, Elliot Cohen
Wellness and Psychedelics: Academic studies show psychedelics, in clinical settings with therapy, rapidly improve psychiatric conditions. Survey of 3,000 adults found significant improvements in mental health with psychedelic use.
Saundra Jain
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Amanda Feilding, Founder of the Beckley Foundation, drives the Psychedelic Renaissance with groundbreaking research programs at top institutions worldwide, including pioneering studies on psilocybin, LSD, MDMA, and DMT.
Study on ibogaine for methadone dependence treatment aims to establish safe detox protocol through first Phase-II trial. Weekly low-dose evaluations conducted to gather safety and efficacy data for future research.
Jose Carlos Bouso
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.